Assessment of the integrity of study blindness in a pediatric clinical trial of risperidone

Benedetto Vitiello, Mark Davies, L. Eugene Arnold, Christopher J. McDougle, Michael Aman, James T. McCracken, Lawrence Scahill, Elaine Tierney, David J. Posey, Naomi Swiezy, Kathleen Koenig

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objective: Controlled clinical trials in pediatric psychopharmacology rely on blinded parents and clinical evaluators for outcome data, but little is known about the success of the masking procedures. The blindness of clinical evaluators and parents was examined in a clinical trial of risperidone in autism. Methods: Clinical evaluators and parents were asked to guess individual treatment assignments at the end of an 8-week placebo-controlled trial of risperidone in children (aged 5-17 years) with autism. Clinical evaluators did not have access to adverse event data. Results: The rates of correctly guessing individual treatment assignment (risperidone or placebo) were significantly greater than chance for both clinical evaluators and parents (P < 0.001). Clinical evaluators associated improvement with attribution to risperidone, and lack of improvement with attribution to placebo, in both the risperidone and placebo treatment arms. Parents associated improvement with attribution to risperidone only in the placebo treatment arm. Parents reported that adverse events influenced their guesses, but presence of adverse events was not associated with correctness of guess. Conclusion: Improvement was associated with attribution to active treatment regardless of actual treatment assignment, and adverse events did not appear to be a threat to study blindness.

Original languageEnglish
Pages (from-to)565-569
Number of pages5
JournalJournal of Clinical Psychopharmacology
Volume25
Issue number6
DOIs
StatePublished - Dec 2005

Fingerprint

Risperidone
Blindness
Parents
Clinical Trials
Pediatrics
Placebos
Autistic Disorder
Therapeutics
Psychopharmacology
Controlled Clinical Trials

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Vitiello, B., Davies, M., Arnold, L. E., McDougle, C. J., Aman, M., McCracken, J. T., ... Koenig, K. (2005). Assessment of the integrity of study blindness in a pediatric clinical trial of risperidone. Journal of Clinical Psychopharmacology, 25(6), 565-569. https://doi.org/10.1097/01.jcp.0000185426.08268.92

Assessment of the integrity of study blindness in a pediatric clinical trial of risperidone. / Vitiello, Benedetto; Davies, Mark; Arnold, L. Eugene; McDougle, Christopher J.; Aman, Michael; McCracken, James T.; Scahill, Lawrence; Tierney, Elaine; Posey, David J.; Swiezy, Naomi; Koenig, Kathleen.

In: Journal of Clinical Psychopharmacology, Vol. 25, No. 6, 12.2005, p. 565-569.

Research output: Contribution to journalArticle

Vitiello, B, Davies, M, Arnold, LE, McDougle, CJ, Aman, M, McCracken, JT, Scahill, L, Tierney, E, Posey, DJ, Swiezy, N & Koenig, K 2005, 'Assessment of the integrity of study blindness in a pediatric clinical trial of risperidone', Journal of Clinical Psychopharmacology, vol. 25, no. 6, pp. 565-569. https://doi.org/10.1097/01.jcp.0000185426.08268.92
Vitiello, Benedetto ; Davies, Mark ; Arnold, L. Eugene ; McDougle, Christopher J. ; Aman, Michael ; McCracken, James T. ; Scahill, Lawrence ; Tierney, Elaine ; Posey, David J. ; Swiezy, Naomi ; Koenig, Kathleen. / Assessment of the integrity of study blindness in a pediatric clinical trial of risperidone. In: Journal of Clinical Psychopharmacology. 2005 ; Vol. 25, No. 6. pp. 565-569.
@article{b6e688d43ac04caabaa0f2300eb86a98,
title = "Assessment of the integrity of study blindness in a pediatric clinical trial of risperidone",
abstract = "Objective: Controlled clinical trials in pediatric psychopharmacology rely on blinded parents and clinical evaluators for outcome data, but little is known about the success of the masking procedures. The blindness of clinical evaluators and parents was examined in a clinical trial of risperidone in autism. Methods: Clinical evaluators and parents were asked to guess individual treatment assignments at the end of an 8-week placebo-controlled trial of risperidone in children (aged 5-17 years) with autism. Clinical evaluators did not have access to adverse event data. Results: The rates of correctly guessing individual treatment assignment (risperidone or placebo) were significantly greater than chance for both clinical evaluators and parents (P < 0.001). Clinical evaluators associated improvement with attribution to risperidone, and lack of improvement with attribution to placebo, in both the risperidone and placebo treatment arms. Parents associated improvement with attribution to risperidone only in the placebo treatment arm. Parents reported that adverse events influenced their guesses, but presence of adverse events was not associated with correctness of guess. Conclusion: Improvement was associated with attribution to active treatment regardless of actual treatment assignment, and adverse events did not appear to be a threat to study blindness.",
author = "Benedetto Vitiello and Mark Davies and Arnold, {L. Eugene} and McDougle, {Christopher J.} and Michael Aman and McCracken, {James T.} and Lawrence Scahill and Elaine Tierney and Posey, {David J.} and Naomi Swiezy and Kathleen Koenig",
year = "2005",
month = "12",
doi = "10.1097/01.jcp.0000185426.08268.92",
language = "English",
volume = "25",
pages = "565--569",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Assessment of the integrity of study blindness in a pediatric clinical trial of risperidone

AU - Vitiello, Benedetto

AU - Davies, Mark

AU - Arnold, L. Eugene

AU - McDougle, Christopher J.

AU - Aman, Michael

AU - McCracken, James T.

AU - Scahill, Lawrence

AU - Tierney, Elaine

AU - Posey, David J.

AU - Swiezy, Naomi

AU - Koenig, Kathleen

PY - 2005/12

Y1 - 2005/12

N2 - Objective: Controlled clinical trials in pediatric psychopharmacology rely on blinded parents and clinical evaluators for outcome data, but little is known about the success of the masking procedures. The blindness of clinical evaluators and parents was examined in a clinical trial of risperidone in autism. Methods: Clinical evaluators and parents were asked to guess individual treatment assignments at the end of an 8-week placebo-controlled trial of risperidone in children (aged 5-17 years) with autism. Clinical evaluators did not have access to adverse event data. Results: The rates of correctly guessing individual treatment assignment (risperidone or placebo) were significantly greater than chance for both clinical evaluators and parents (P < 0.001). Clinical evaluators associated improvement with attribution to risperidone, and lack of improvement with attribution to placebo, in both the risperidone and placebo treatment arms. Parents associated improvement with attribution to risperidone only in the placebo treatment arm. Parents reported that adverse events influenced their guesses, but presence of adverse events was not associated with correctness of guess. Conclusion: Improvement was associated with attribution to active treatment regardless of actual treatment assignment, and adverse events did not appear to be a threat to study blindness.

AB - Objective: Controlled clinical trials in pediatric psychopharmacology rely on blinded parents and clinical evaluators for outcome data, but little is known about the success of the masking procedures. The blindness of clinical evaluators and parents was examined in a clinical trial of risperidone in autism. Methods: Clinical evaluators and parents were asked to guess individual treatment assignments at the end of an 8-week placebo-controlled trial of risperidone in children (aged 5-17 years) with autism. Clinical evaluators did not have access to adverse event data. Results: The rates of correctly guessing individual treatment assignment (risperidone or placebo) were significantly greater than chance for both clinical evaluators and parents (P < 0.001). Clinical evaluators associated improvement with attribution to risperidone, and lack of improvement with attribution to placebo, in both the risperidone and placebo treatment arms. Parents associated improvement with attribution to risperidone only in the placebo treatment arm. Parents reported that adverse events influenced their guesses, but presence of adverse events was not associated with correctness of guess. Conclusion: Improvement was associated with attribution to active treatment regardless of actual treatment assignment, and adverse events did not appear to be a threat to study blindness.

UR - http://www.scopus.com/inward/record.url?scp=27944444059&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27944444059&partnerID=8YFLogxK

U2 - 10.1097/01.jcp.0000185426.08268.92

DO - 10.1097/01.jcp.0000185426.08268.92

M3 - Article

C2 - 16282839

AN - SCOPUS:27944444059

VL - 25

SP - 565

EP - 569

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 6

ER -